VHL, Jade-1 and protein stability in renal cancer
VHL, Jade-1 and protein stability in renal cancer
批准号:
7227198
负责人:
HERBERT TOD COHEN
金额:
$30.53万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1999
资助国家:
美国
项目状态:
已结题
起止时间:
1999-04-01 至 2009-04-30
关键词:
AdultAnoikisApoptosisApoptoticBiologicalCancer EtiologyCell AdhesionCellsChromatinClinicalDegradation PathwayDevelopmentDiseaseEpithelial CellsEpitheliumGene ExpressionGene ProteinsGenesHomeodomain ProteinsHypoxiaKidneyKnockout MiceLaboratoriesLifeMalignant NeoplasmsMalignant neoplasm of kidneyMediatingMedicalMicroarray AnalysisMissense MutationModelingModificationMutateNatureNuclearOncogenesPathway interactionsPlantsPost-Translational Protein ProcessingProteasome InhibitorProtein FamilyProteinsRenal carcinomaResistanceRoleStressSuppressor MutationsTechniquesTestingTissuesTumor SuppressionTumor Suppressor ProteinsVon Hippel-Lindau Tumor Suppressor Proteinbasebiological adaptation to stresscancer riskcell growthclinically relevantdesignmembermonolayermulticatalytic endopeptidase complexnovelpro-apoptotic proteinprotein protein interactiontherapeutic targettranscription factortumorigenesis
中文摘要
肾癌是一种对药物治疗具有高度抵抗力的毁灭性恶性肿瘤。VHL肿瘤
在大多数成人肾癌中抑制基因突变。然而,VHL肿瘤抑制的机制是
不知道。使用定向方法来寻找在肾癌中重要的VHL相互作用蛋白,
一个实验室已经鉴定出Jade-1(上皮细胞凋亡和分化基因)是一种特别的
强VHL相互作用。Jade-1是一种新的肾脏富集的PEST和植物同源结构域蛋白,
一个新的蛋白质家族。Jade-1是蛋白酶体降解的短寿命靶点
途径,是强烈的促凋亡,因为它减少细胞粘附,并直接促进
染色质致密化VHL阻断Jade-l诱导的细胞凋亡并稳定Jade-l蛋白,其是
新的VHL功能。此外,我们现在已经表明,Jade-1稳定化是VHL
突变依赖性,非肾癌引起的VHL错义突变能够稳定Jade-1
类似于野生型VHL。因此,Jade-1稳定化是第一个显示出显著的VHL活性的VHL活性。
与肾癌风险的相关性,表明它与疾病有关。Jade-1的稳定化
VHL是高度特异性的,因为它尚未与已知或潜在的VHL合作伙伴观察到。玉-1是
低氧诱导的VHL依赖性的方式,并显示改变的翻译后的证据
在条件性VHL缺失小鼠中的修饰。我们已经有了确凿的证据,
VHL-Jade-1关系的真实性以及Jade-1引人注目的生物学意义。我们
提出以下目标:
1. VHL-Jade-1蛋白相互作用及Jade-1在肾癌组织中的表达
2. VHL依赖性Jade-1稳定化和修饰
3. Jade-1在细胞凋亡和细胞应激中的作用及VHL的调节作用
4. Jade-1作为转录因子与染色质致密化及VHL的调节
英文摘要
Renal cancer is a devastating malignancy that is highly resistant to medical therapy. The VHL tumor
suppressor is mutated in most adult renal cancers. Yet, the mechanism of VHL tumor suppression is
not known. Using a directed approach to find VHL-interacting proteins important in renal cancer, our
laboratory has identified Jade-1 (gene for Apoptosis and Differentiation in Epithelia) as a particularly
strong VHL interactor. Jade-l, a novel, kidney-enriched, PEST and plant homeodomain protein, is a
member of a new protein family. Jade-1 is a short-lived target of the proteasome degradation
pathway and is strongly pro-apoptotic, as it decreases cellular adhesion and directly promotes
chromatin compaction. VHL blocks Jade-l-induced apoptosis and stabilizes Jade-1 protein, which is
a new VHL function. Moreover, we have now shown that Jade-1 stabilization is VHL
mutation-dependent, with non-renal cancer-causing VHL missense mutations able to stabilize Jade-1
like wild-type VHL. Jade-1 stabilization is therefore the first VHL activity to show substantial
correlation with renal cancer risk, suggesting it has a disease relationship. Stabilization of Jade-1 by
VHL is highly specific, as it has not been observed with known or potential VHL partners. Jade-1 is
hypoxia-inducible in a VHL dependent manner and shows evidence of altered post-translational
modification in conditional VHL null mice. Thus, we have established convincing evidence of the
VHL-Jade-1 relationship's authenticity as well as Jade-1 's compelling biological significance. We
propose the following Aims:
1. The VHL-Jade-1 protein-protein interaction, and Jade-1 expression in renal cancer tissue
2. VHL-dependent Jade-1 stabilization and modification
3. Jade-1 in apoptosis and cell stress, and modulation by VHL
4. Jade-1 as a transcription factor and in chromatin compaction, and modulation by VHL
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Jade-1 in cystic renal disease
-
批准号:6861859
-
项目类别:
-
资助金额:$31.88万
-
财政年份:2004
-
负责人:HERBERT TOD COHEN
-
依托单位:
Jade-1 in cystic renal disease
-
批准号:7049325
-
项目类别:
-
资助金额:$31.13万
-
财政年份:2004
-
负责人:HERBERT TOD COHEN
-
依托单位:
Jade-1 in cystic renal disease
-
批准号:6768201
-
项目类别:
-
资助金额:$31.88万
-
财政年份:2004
-
负责人:HERBERT TOD COHEN
-
依托单位:
Jade-1 in cystic renal disease
-
批准号:7379930
-
项目类别:
-
资助金额:$29.62万
-
财政年份:2004
-
负责人:HERBERT TOD COHEN
-
依托单位:
Jade-1 in cystic renal disease
-
批准号:7234711
-
项目类别:
-
资助金额:$30.23万
-
财政年份:2004
-
负责人:HERBERT TOD COHEN
-
依托单位:
VHL, Jade-1 and protein stability in renal cancer
-
批准号:6686928
-
项目类别:
-
资助金额:$32.2万
-
财政年份:1999
-
负责人:HERBERT TOD COHEN
-
依托单位:
VEGF TRANSCRIPTIONAL REGULATION BY TUMOR SUPPRESSOR VHL
-
批准号:2733434
-
项目类别:
-
资助金额:$31.63万
-
财政年份:1999
-
负责人:HERBERT TOD COHEN
-
依托单位:
The pVHL/Jade-1/beta-catenin axis in renal cancer
-
批准号:8585027
-
项目类别:
-
资助金额:$31.06万
-
财政年份:1999
-
负责人:HERBERT TOD COHEN
-
依托单位:
The pVHL/Jade-1/beta-catenin axis in renal cancer
-
批准号:8196861
-
项目类别:
-
资助金额:$32.02万
-
财政年份:1999
-
负责人:HERBERT TOD COHEN
-
依托单位:
VEGF TRANSCRIPTIONAL REGULATION BY TUMOR SUPPRESSOR VHL
-
批准号:6173732
-
项目类别:
-
资助金额:$29.27万
-
财政年份:1999
-
负责人:HERBERT TOD COHEN
-
依托单位:
VHL, Jade-1 and protein stability in renal cancer
-
批准号:6919315
-
项目类别:
-
资助金额:$32.2万
-
财政年份:1999
-
负责人:HERBERT TOD COHEN
-
依托单位:
The pVHL/Jade-1/beta-catenin axis in renal cancer
-
批准号:8578133
-
项目类别:
-
资助金额:$6.48万
-
财政年份:1999
-
负责人:HERBERT TOD COHEN
-
依托单位:
The pVHL/Jade-1/beta-catenin axis in renal cancer
-
批准号:7999259
-
项目类别:
-
资助金额:$32.02万
-
财政年份:1999
-
负责人:HERBERT TOD COHEN
-
依托单位:
The pVHL/Jade-1/beta-catenin axis in renal cancer
-
批准号:8787179
-
项目类别:
-
资助金额:$6.69万
-
财政年份:1999
-
负责人:HERBERT TOD COHEN
-
依托单位:
VEGF TRANSCRIPTIONAL REGULATION BY TUMOR SUPPRESSOR VHL
-
批准号:6376964
-
项目类别:
-
资助金额:$33.55万
-
财政年份:1999
-
负责人:HERBERT TOD COHEN
-
依托单位:
The pVHL/Jade-1/beta-catenin axis in renal cancer
-
批准号:8527928
-
项目类别:
-
资助金额:$2.23万
-
财政年份:1999
-
负责人:HERBERT TOD COHEN
-
依托单位:
The pVHL/Jade-1/beta-catenin axis in renal cancer
-
批准号:8387038
-
项目类别:
-
资助金额:$30.1万
-
财政年份:1999
-
负责人:HERBERT TOD COHEN
-
依托单位:
VHL, Jade-1 and protein stability in renal cancer
-
批准号:6777002
-
项目类别:
-
资助金额:$32.2万
-
财政年份:1999
-
负责人:HERBERT TOD COHEN
-
依托单位:
VHL, Jade-1 and protein stability in renal cancer
-
批准号:7084646
-
项目类别:
-
资助金额:$31.44万
-
财政年份:1999
-
负责人:HERBERT TOD COHEN
-
依托单位:
The pVHL/Jade-1/beta-catenin axis in renal cancer
-
批准号:7782104
-
项目类别:
-
资助金额:$33.01万
-
财政年份:1999
-
负责人:HERBERT TOD COHEN
-
依托单位:
国内基金
海外基金
登录
查看更多内容
胃肠安方抑制整合素αvβ6促进胃癌细胞Anoikis防治胃癌转移的机制研究
-
批准号:82305335
-
项目类别:青年科学基金项目
-
资助金额:30万元
-
批准年份:2023
-
负责人:卢艳琳
-
依托单位:
AMPK通路调控CEMIP诱导自噬对前列腺癌细胞anoikis耐受的影响及机制
-
批准号:81772751
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2017
-
负责人:邢毅飞
-
依托单位:
Myxoma 病毒蛋白Serp-1促进肝癌细胞Anoikis的作用及机制研究
-
批准号:81372597
-
项目类别:面上项目
-
资助金额:16.0万元
-
批准年份:2013
-
负责人:陈昊
-
依托单位:
TrkB/BDNF通路对前列腺癌EMT、anoikis和血管生成的影响及分子机制
-
批准号:81272847
-
项目类别:面上项目
-
资助金额:60.0万元
-
批准年份:2012
-
负责人:邢毅飞
-
依托单位:
E-cadherin调控卵巢癌细胞anoikis-resistance的分子机制及干预
-
批准号:81172487
-
项目类别:面上项目
-
资助金额:60.0万元
-
批准年份:2011
-
负责人:刘联
-
依托单位:
NDRG1在肝癌细胞抵抗Anoikis中的作用及其机制研究
-
批准号:30873025
-
项目类别:面上项目
-
资助金额:30.0万元
-
批准年份:2008
-
负责人:曹莉莉
-
依托单位:
肝癌细胞抵抗anoikis关键分子的筛选和鉴定
-
批准号:30700357
-
项目类别:青年科学基金项目
-
资助金额:17.0万元
-
批准年份:2007
-
负责人:韩丽辉
-
依托单位:
阻遏供体鼠胰岛整合素介导的Anoikis延长移植胰岛存活率
-
批准号:30070724
-
项目类别:面上项目
-
资助金额:15.0万元
-
批准年份:2000
-
负责人:吴育连
-
依托单位: